{"id":634377,"date":"2023-01-17T16:44:02","date_gmt":"2023-01-17T16:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634377"},"modified":"2023-01-17T16:44:02","modified_gmt":"2023-01-17T16:44:02","slug":"multiple-myeloma-market-to-observe-stupendous-growth-during-the-forecast-period-201932-delveinsight-key-companies-iaso-biotherapeutics-janssen-oncopeptides-ab-casi-pharma-gsk-abbvie","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-myeloma-market-to-observe-stupendous-growth-during-the-forecast-period-201932-delveinsight-key-companies-iaso-biotherapeutics-janssen-oncopeptides-ab-casi-pharma-gsk-abbvie_634377.html","title":{"rendered":"Multiple Myeloma Market to Observe Stupendous Growth During the Forecast Period (2019-32) – DelveInsight | Key Companies – IASO Biotherapeutics, Janssen, Oncopeptides AB, CASI Pharma, GSK, AbbVie"},"content":{"rendered":"
\n
\"Multiple<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Multiple Myeloma Market dynamics are anticipated to change in the coming years owing to the increase in incident cases of Multiple Myeloma, the launch of novel drugs, and the expected increase in investment in R&D activities worldwide.<\/div>\n

Several major pharma and biotech giants, such as AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca,<\/strong> and others, are involved in developing drugs for Multiple Myeloma. The launch of emerging therapies is anticipated to transform the treatment scenario in the coming years. <\/em><\/p>\n

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Myeloma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Multiple Myeloma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Multiple<\/p>\n

Multiple Myeloma: An Overview<\/strong><\/p>\n

According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system.<\/p>\n

Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. Multiple Myeloma is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74. Approximately 95% of cases are diagnosed at a distant or metastatic stage, and 5-year relative survival rate for this stage is around 53%.<\/p>\n

Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment to reduce or at least relieve symptoms and reduce the number of myeloma cells in the bone marrow.<\/em><\/p>\n

Multiple Myeloma Market Key Facts<\/strong><\/p>\n